On May 18, 2016 Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, reported that data related to galeterone will be presented in two posters at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will take place from June 3-7, 2016, in Chicago (Press release, Tokai Pharmaceuticals, MAY 18, 2016, View Source;p=irol-newsArticle&ID=2169534 [SID:1234512555]). Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistance prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Galeterone in treatment‐naïve patients with castration‐resistant prostate cancer with C‐terminal androgen receptor loss: Results from ARMOR2
Presenting author: Mary-Ellen Taplin, M.D., Associate Professor, Medicine, Harvard Medical School, and Chair, Executive Committee for Clinical Research, Dana-Farber Cancer Institute
Date/time: Saturday, June 4, 2016, 1 – 4:30 p.m. CDT
Location: Hall A
Abstract: 5064
Title: Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV)
Presenting author: Emmanuel Antonarakis, M.D., Associate Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Date/time: Saturday, June 4, 2016, 1 – 4:30 p.m. CDT
Location: Hall A
Abstract: TPS5085
A third abstract, "Galeterone targets proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC," was accepted for publication.
Additional information, including the presentation schedule and full abstracts, may be found at abstracts.asco.org. A copy of each presentation will be available on the "Publications & Presentations" page of Tokai’s website, www.tokaipharmaceuticals.com, after being presented at the meeting.
About Galeterone
Galeterone is an oral small molecule that utilizes the established pathways, including CYP17 enzyme and androgen receptor inhibition, of the current second-generation hormonal therapies abiraterone and enzalutamide. Galeterone also introduces a distinct third mechanism – androgen receptor degradation – that impairs the function of androgen receptors, decreasing their sensitivity to androgen activity and reducing tumor growth. Tokai is developing galeterone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). ARMOR3-SV, the company’s pivotal Phase 3 study of galeterone in treatment-naive mCRPC patients whose prostate tumors express the AR-V7 splice variant, is evaluating whether administration of galeterone results in a statistically significant increase in radiographic progression-free survival as compared to enzalutamide. Tokai is also evaluating galeterone in mCRPC patients who have shown resistance following treatment with second-generation hormonal agents. Tokai has worldwide development and commercialization rights to galeterone.